Successful treatment of lower eyelid epiblepharon by injection of botulinum toxin A in patients under two years of age
| Autor: | CY Chen, Angel Nava-Castaneda |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
medicine.medical_specialty business.product_category Neurotoxins Remission Spontaneous Corneal Diseases Cornea medicine Humans Epiblepharon Prospective Studies Botulinum Toxins Type A Prospective cohort study Mexico Eyelashes business.industry Eyelids Infant Lower eyelid epiblepharon General Medicine medicine.disease Botulinum toxin Surgery Clinical trial medicine.anatomical_structure Treatment Outcome Oculomotor Muscles Eyelid Diseases Female Eyelid Eyelash business medicine.drug |
| Zdroj: | Nepalese journal of ophthalmology : a biannual peer-reviewed academic journal of the Nepal Ophthalmic Society : NEPJOPH. 5(2) |
| ISSN: | 2072-6805 |
| Popis: | Introduction: Epiblepharon is characterized by a cutaneous horizontal fold adjacent to the lid margin. Some cases showed spontaneous resolution, others required surgical treatment. We propose a medical treatment with botulinum toxin type A (BTX-A). Objective: To provide clinical evidence of the usefulness of botulinum toxin type A (BTX-A) in patients with lower eyelid epiblepharon. Subjects and methods: This was a prospective, non-randomized, nonmasked study. Patients with lower eyelid epiblepharon with corneal eyelash contact were included in the study. The scale proposed by Khwarg & Lee (1997) was used to assess the epiblepharon clinical evaluation. A single dose of 12.5 IU of BTX-A (Dysport ®) was directly injected into the medial pre-tarsal orbicularis muscle region in the lower eyelid. Patients were evaluated before the injection and at 1, 4, 12 and 24 weeks after the injection. We performed descriptive statistics and Wilcoxon Signed Rank Test, comparing prior injection measurements to post injection measurements at the 24th week. A p < 0.05 was considered statistically significant. Each eye was separately analyzed. Results: Fourteen eyes of seven Hispanic patients were treated, five female and two male. The mean age was 8.4 months (4 - 14 months). The height of the skin-fold, the area of the cornea touched by the cilia and the symptoms score improved after the first week of BTX-A injection and remained so until the end of study (p < 0.05). No major complications were noted. Conclusion: The effect of a single 12.5 IU injection of BTX-A (Dysport ®) into the medial orbicularis muscle portion in the lower eyelid epiblepharon patients successfully improves the clinical signs and symptoms. Nepal J Ophthalmol 2013; 5(10): 177-181 DOI: http://dx.doi.org/10.3126/nepjoph.v5i2.8709 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|